Anuh Pharma Ltd
₹ 79.3
0.66%
12 Dec
- close price
About
Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals[1]
Key Points
- Market Cap ₹ 795 Cr.
- Current Price ₹ 79.3
- High / Low ₹ 123 / 74.0
- Stock P/E 20.5
- Book Value ₹ 32.6
- Dividend Yield 1.89 %
- ROCE 17.2 %
- ROE 13.4 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 21.5%
- Promoter holding has increased by 1.90% over last quarter.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 266 | 284 | 326 | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 730 | |
| 242 | 253 | 289 | 183 | 220 | 291 | 284 | 387 | 439 | 476 | 571 | 600 | 674 | |
| Operating Profit | 24 | 31 | 38 | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 76 | 62 | 56 |
| OPM % | 9% | 11% | 12% | 11% | 8% | 9% | 8% | 10% | 10% | 10% | 12% | 9% | 8% |
| 4 | 5 | 4 | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 12 | 9 | 7 | |
| Interest | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 2 | 3 | 2 | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 | 9 | 10 |
| Profit before tax | 25 | 32 | 38 | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 78 | 61 | 51 |
| Tax % | 31% | 31% | 32% | 27% | 29% | 28% | 25% | 26% | 22% | 24% | 23% | 22% | |
| 18 | 22 | 26 | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | 47 | 39 | |
| EPS in Rs | 1.76 | 2.19 | 2.57 | 2.00 | 1.65 | 2.33 | 1.43 | 2.84 | 3.05 | 3.61 | 5.99 | 4.73 | 3.86 |
| Dividend Payout % | 37% | 27% | 24% | 31% | 42% | 29% | 48% | 26% | 29% | 28% | 21% | 16% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 17% |
| 3 Years: | 11% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 26% |
| 3 Years: | 13% |
| TTM: | -34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 4% |
| 3 Years: | 20% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 15% |
| 3 Years: | 16% |
| Last Year: | 13% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 13 | 13 | 13 | 13 | 13 | 25 | 25 | 25 | 25 | 25 | 50 |
| Reserves | 82 | 97 | 107 | 128 | 137 | 152 | 150 | 166 | 189 | 216 | 266 | 301 | 277 |
| 0 | 0 | 2 | 0 | 2 | 4 | 45 | 14 | 4 | 1 | 3 | 11 | 0 | |
| 77 | 67 | 71 | 48 | 57 | 71 | 119 | 128 | 129 | 163 | 152 | 170 | 182 | |
| Total Liabilities | 163 | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 509 |
| 12 | 9 | 18 | 17 | 17 | 21 | 84 | 71 | 61 | 53 | 49 | 58 | 61 | |
| CWIP | 0 | 0 | 0 | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 27 | 43 | 43 | 70 | 66 | 39 | 80 | 31 | 43 | 91 | 97 | 106 | 71 |
| 124 | 116 | 131 | 101 | 120 | 147 | 163 | 230 | 243 | 261 | 300 | 342 | 376 | |
| Total Assets | 163 | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 509 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 | 19 | 16 | 26 | 2 | 7 | 49 | -19 | 29 | 54 | 13 | 37 | |
| -5 | -12 | -5 | -20 | 2 | 3 | -77 | 52 | -8 | -43 | 1 | -20 | |
| -8 | -8 | -9 | -4 | -5 | -7 | 22 | -33 | -19 | -12 | -9 | -5 | |
| Net Cash Flow | 2 | -1 | 2 | 2 | -1 | 3 | -5 | 0 | 2 | -2 | 5 | 12 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102 | 88 | 84 | 100 | 109 | 85 | 96 | 90 | 102 | 118 | 107 | 119 |
| Inventory Days | 33 | 27 | 35 | 72 | 64 | 64 | 98 | 90 | 77 | 66 | 57 | 54 |
| Days Payable | 102 | 79 | 77 | 102 | 105 | 89 | 166 | 133 | 117 | 139 | 105 | 115 |
| Cash Conversion Cycle | 33 | 36 | 42 | 70 | 68 | 61 | 28 | 48 | 62 | 46 | 58 | 59 |
| Working Capital Days | 42 | 43 | 48 | 79 | 80 | 65 | -10 | 57 | 68 | 61 | 69 | 68 |
| ROCE % | 31% | 33% | 35% | 19% | 14% | 19% | 10% | 16% | 18% | 19% | 26% | 17% |
Documents
Announcements
-
Announcement Under Regulation 30 (LODR) - Updates
5 Dec - Anuh Pharma received EDQM CEP for Sulfadimethoxine, dated 05-Dec-2025, enabling regulated market access.
- Announcement under Regulation 30 (LODR)-Investor Presentation 17 Nov
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Nov - Newspaper publication of the Un-Audited financial results for the Quarter and Half year ended 30th September, 2025, published in the Financial Express in English Language …
-
Announcement Under Regulation 30 (LODR) - Adoption Of Revised Polices And Codes
7 Nov - On 7 Nov 2025, Anuh Pharma adopted revised insider-trading, UPSI inquiry, code of conduct, document preservation, CSR policies.
-
Results-Financial Results For September 30, 2025
7 Nov - H1 revenue Rs 37,672.90 lakh; H1 PAT Rs 1,591.37 lakh; 1:1 bonus allotted 16 Jul 2025
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptAI SummaryPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Aug 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Aug 2019TranscriptAI SummaryPPT
-
Dec 2017TranscriptAI SummaryPPT
-
Feb 2016TranscriptAI SummaryPPT
-
Dec 2015TranscriptAI SummaryPPT
-
Sep 2015TranscriptAI SummaryPPT
-
Aug 2015TranscriptAI SummaryPPT
Business Overview:[1][2]
a) APL is a part of the SK Group and is a leading manufacturer of Macrolides and Anti-TB products in India, besides being a major player in Anti-bacterials, Anti-malarial, Anti-hypertension, and Corticosteroids.
b) It is a medium-sized player in the API/bulk drugs industry, manufacturing products such as erythromycin and its salts, and higher macrolides like azithromycin, roxithromycin, pyrazinamide, and chloramphenicol.
c) The company claims to be the largest producer of erythromycin salts in India and among the top five globally. It is also the largest producer of pyrazinamide in the world.
d) APL has marketing partnerships with 350 customers in over 57 countries, including Europe, Mexico, and South Africa.